Quick Answer
ARS Pharmaceuticals, Inc. reported Total Revenue of $84.28 million for fiscal year 2025.
ARS Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $84.28M -5.5% |
$89.15M +297063.3% |
$30.0K -97.7% |
$1.32M -76.1% |
$5.51M | — |
| Revenue (ASC 606) | $84.28M -5.5% |
$89.15M +297063.3% |
$30.0K -97.7% |
$1.32M -76.1% |
$5.51M | — |
| Net Income | -$171.30M -2241.8% |
$8.00M +114.7% |
-$54.37M -56.8% |
-$34.68M -71.3% |
-$20.24M +38.6% |
-$32.95M |
| Diluted EPS | -$1.74 -2275.0% |
$0.08 +114.0% |
-$0.57 +34.5% |
-$0.87 -24.3% |
-$0.70 | — |
| Total Assets | $327.65M -6.7% |
$351.15M +50.6% |
$233.19M -17.1% |
$281.44M +358.0% |
$61.45M -84.4% |
$394.80M |
| Cash and Equivalents | $41.32M -18.7% |
$50.82M -28.4% |
$70.97M -66.3% |
$210.52M +250.5% |
$60.06M -84.5% |
$386.57M |
| Long-Term Debt | $96.37M | $0.00 | — | — | — | — |
| Stockholders Equity | $114.26M -55.5% |
$256.80M +11.3% |
$230.76M -15.4% |
$272.89M +972.7% |
-$31.27M -122.5% |
-$14.05M +76.1% |
| R&D Expense | $13.18M -32.7% |
$19.58M -3.4% |
$20.27M +10.3% |
$18.38M -9.4% |
$20.27M -17.5% |
$24.58M |
| Operating Income | -$179.45M -5720.6% |
-$3.08M +95.4% |
-$67.52M -90.1% |
-$35.52M -82.6% |
-$19.45M +40.9% |
-$32.92M |
| Shares Outstanding | 99.29M +1.4% |
97.95M +1.6% |
96.41M +2.6% |
93.94M +209.3% |
30.37M -12.5% |
34.70M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $32.50M | +1471.6% | +106.8% |
| Revenue (ASC 606) | September 30, 2025 | $32.50M | +1471.6% | +106.8% |
| Net Income | September 30, 2025 | -$51.15M | -167.4% | -14.0% |
| Diluted EPS | September 30, 2025 | -$0.52 | -160.0% | -13.0% |
| Total Assets | September 30, 2025 | $372.80M | +71.3% | +18.9% |
| Cash and Equivalents | September 30, 2025 | $59.56M | +50.2% | +15.6% |
| Long-Term Debt | September 30, 2025 | $96.23M | — | — |
| Stockholders Equity | September 30, 2025 | $147.66M | -26.5% | -23.2% |
| R&D Expense | September 30, 2025 | $2.75M | -37.8% | -31.8% |
| Operating Income | September 30, 2025 | -$53.19M | -144.6% | -11.7% |
| Shares Outstanding | September 30, 2025 | 98.84M | +1.7% | +0.1% |
- ARS Pharmaceuticals, Inc. reported Total Revenue of $84.28 million for fiscal year 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -5.5% in Total Revenue compared to the prior fiscal year.
- ARS Pharmaceuticals, Inc. reported Revenue (ASC 606) of $84.28 million for fiscal year 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -5.5% in Revenue (ASC 606) compared to the prior fiscal year.
- ARS Pharmaceuticals, Inc. reported Net Income of -$171.30 million for fiscal year 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -2241.8% in Net Income compared to the prior fiscal year.
- ARS Pharmaceuticals, Inc. reported Diluted EPS of $1.74 per share (loss) for fiscal year 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -2275.0% in Diluted EPS compared to the prior fiscal year.
- ARS Pharmaceuticals, Inc. reported Total Assets of $327.65 million for fiscal year 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -6.7% in Total Assets compared to the prior fiscal year.
- ARS Pharmaceuticals, Inc. reported Cash and Equivalents of $41.32 million for fiscal year 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -18.7% in Cash and Equivalents compared to the prior fiscal year.
- ARS Pharmaceuticals, Inc. reported Long-Term Debt of $96.37 million for fiscal year 2025.
- ARS Pharmaceuticals, Inc. reported Stockholders Equity of $114.26 million for fiscal year 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -55.5% in Stockholders Equity compared to the prior fiscal year.
- ARS Pharmaceuticals, Inc. reported R&D Expense of $13.18 million for fiscal year 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -32.7% in R&D Expense compared to the prior fiscal year.
- ARS Pharmaceuticals, Inc. reported Operating Income of -$179.45 million for fiscal year 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -5720.6% in Operating Income compared to the prior fiscal year.
- ARS Pharmaceuticals, Inc. reported Shares Outstanding of 99.29 million shares for fiscal year 2025.
- ARS Pharmaceuticals, Inc. showed an increase of +1.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: